Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Nov 13, 2023 2:59pm
116 Views
Post# 35732617

RE:RE:Acumen Pharma Quarterly

RE:RE:Acumen Pharma Quarterly No meaniful news coming from them for probably quite some time. ACU 193 a one trick pony their only product, Phase 1 just wrapped after 2 years in the clinic, phase 2 expected to start in the second half of 2024. A long haul in clinic trials with many possible setbacks. They do seem to have a very qualified team with sound technical data it appears. Can't say i understand it! You have to give them credit raising cash $170 million at $16/share in 2021 and $130 milion at $7.75/share this summer. 
Not suprized about the share price you don't get many investors excited after phase 1 results just provide confirmation you can keep going.
Short interest jumped from 150 K in June to 2 million in Sept/Oct, 
What is Promis going to do with all of their Pony's AD, PD, ALS, Vaccine development, etc.
<< Previous
Bullboard Posts
Next >>